Ozempic is a registered trademark of Novo Nordisk A/S. It is an FDA-approved prescription medicine containing semaglutide. A licensed clinician must evaluate a patient and determine whether it is appropriate.
Important safety information
Ozempic carries a boxed warning about the risk of thyroid C-cell tumors. Semaglutide caused thyroid C-cell tumors in rodents. It is not known whether Ozempic causes these tumors, including medullary thyroid carcinoma, in people. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Serious risks in the FDA labeling include pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or certain other diabetes medicines, kidney injury due to dehydration, severe stomach problems, serious allergic reactions, gallbladder problems, and aspiration during anesthesia or deep sedation. Common side effects include nausea, vomiting, diarrhea, stomach pain, and constipation.
Read the official Ozempic Prescribing Information and Medication Guide for the complete boxed warning, approved uses, contraindications, warnings, side effects, and patient instructions. Tell health care professionals about all medicines and any planned surgery or procedure.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
What Ozempic is
Ozempic is the brand name for a prescription injection whose active ingredient is semaglutide. The FDA label classifies semaglutide as a glucagon-like peptide-1, or GLP-1, receptor agonist. It acts on a receptor involved in blood sugar control, appetite, and digestion.
The medicine comes in a prefilled, single-patient-use pen and is injected under the skin. The FDA labeling directs once-weekly use. It may be taken at any time of day, with or without meals, on the schedule prescribed by the clinician.
The labeling describes injections in the abdomen, thigh, or upper arm. Injection sites should be rotated. A clinician or pharmacist should teach the patient how to use and store the pen. The pen must never be shared, even if the needle is changed.
What the FDA has approved it for
According to the FDA Prescribing Information, Ozempic is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Its approved uses also include reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
The current label also includes reducing the risk of certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. Each approved use has specific clinical context. A clinician reviews diagnoses, health history, current medicines, and risks before deciding whether a prescription is appropriate.
Ozempic is not described in its FDA label as a weight-loss medicine. Another product may contain the same active ingredient yet have a different approved use, dosing schedule, presentation, and labeling. Products should not be treated as interchangeable. A patient should use only the product and dose written on the prescription.
How dosing generally works
The FDA label uses a gradual dosing schedule. Treatment begins with a lower weekly dose, then increases after a set period. A clinician may make further changes if more blood sugar control is needed and the label allows it.
The starting dose is intended to help begin treatment and is not the maintenance plan for every patient. Patients should follow the individual prescription and should not increase early, take extra medicine, or copy another person's schedule.
The Medication Guide explains what to do after a missed dose. Timing matters, so a patient who is unsure should check the written instructions or ask a pharmacist. Taking two doses too close together can be unsafe.
Because Ozempic delays stomach emptying, it may affect how some oral medicines are absorbed. The clinician needs a complete medication list. The label also tells patients to inform health care professionals before anesthesia or deep sedation because delayed stomach emptying can raise aspiration risk.
What a clinical evaluation covers
A clinician may ask about diabetes history, blood sugar measurements, kidney health, eye disease, stomach problems, pancreatitis, gallbladder disease, pregnancy plans, allergies, and personal or family history of certain thyroid cancers. The clinician also reviews prescription medicines, over-the-counter products, and supplements.
Laboratory testing may be appropriate based on the patient's history and care plan. Follow-up gives the clinician a chance to review side effects, response, medication interactions, and whether the prescribed plan remains suitable.
Seek prompt medical guidance for severe or lasting stomach pain, signs of a serious allergic reaction, symptoms of dehydration, vision changes, or other concerning symptoms. The Medication Guide provides a fuller list and explains when urgent help may be needed.
Cost and coverage are separate questions
Clinical eligibility does not guarantee insurance coverage. A health plan may apply a formulary, prior authorization, coverage criteria, quantity limits, deductible, and pharmacy network. The plan decides whether it approves and pays a claim.
Body Good may assist with benefit checks and requested prior authorization paperwork. This is coverage support, not a promise that coverage will be obtained or that a particular amount will be due. The pharmacy controls dispensing and its medication charge.
Body Good's prices are service fees for the program described during intake. They are not the price of medication, and medication cost is separate and not included. Prices are not a quote for any individual. Eligibility is determined by a clinician.
This website is an informational and pricing overview. It accepts no payment, collects no protected health information, and runs no intake form. All intake and checkout happen on joinbodygood.com.
What Body Good provides
Body Good provides access to clinical and administrative services. Depending on the patient's needs and eligibility, the program may include an evaluation by a licensed clinician, ongoing follow-up, pharmacy routing, and coverage support.
An evaluation does not guarantee a prescription. The clinician makes an independent decision based on the patient's medical information. If medication is prescribed, a state-licensed pharmacy dispenses it under its own professional responsibilities.
Frequently asked questions
Is Ozempic insulin?
No. Ozempic is a GLP-1 receptor agonist containing semaglutide. It is not insulin. Some patients may be prescribed it along with insulin, which requires careful clinical oversight because low blood sugar risk can increase.
How often is Ozempic used?
The FDA labeling directs once-weekly injection. The exact dose and schedule come from the prescribing clinician. Patients should not change the day, dose, or missed-dose plan without checking the label or asking their care team.
Can Body Good decide if it is right for me?
A licensed clinician can review your health information and make an independent prescribing decision. No prescription is guaranteed. Begin the secure intake to provide information for clinical review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.